Santhera Expands Capital Markets Advisory Team with Stifel
Event summary
- Santhera Pharmaceuticals appointed Stifel as corporate finance advisor on February 10, 2026.
- Stifel will focus on capital markets and international institutional investors.
- Octavian AG will continue as corporate finance advisor, working alongside Stifel.
- Santhera specializes in rare neuromuscular diseases, with AGAMREE approved in multiple regions.
The big picture
Santhera's appointment of Stifel as a corporate finance advisor signals a strategic push to strengthen its capital markets presence. The move comes as the company seeks to expand its investor reach, particularly in international markets, amid a competitive landscape for rare disease therapies. With AGAMREE approved in multiple regions, Santhera is positioning itself for potential growth, but the effectiveness of its dual-advisor structure will be key to its success.
What we're watching
- Capital Markets Strategy
- How Santhera will leverage Stifel's expertise to broaden investor reach and potentially raise capital.
- Partnership Dynamics
- Whether the dual-advisor structure will create synergies or operational inefficiencies.
- Market Expansion
- The pace at which Santhera can grow its investor base in international markets.
Our editorial coverage:
Related topics